Mr A.L. Gray

Mr A.L. Gray

Person

Mr A L Gray

 

Telephone

+27 (0)31 260 4298                             

Email

graya1@ukzn.ac.za  

Campus

Medical School

Designation

Senior Lecturer

 

Research

Interests

 1.      Policy analysis (particularly the processes of development and implementation of Medicines             Policies)

2.       Rational medicines use (particularly in the elderly and in relation to antimicrobial use).

3.       The application of combination antiretroviral therapy (cART) in resource-constrained settings.

Biosketch

Andy Gray B Pharm, MSc (Pharm), FPS, FFIP is a pharmacist whose research interests include policy analysis (in particular, the development and implementation of National Medicines Policies), rational medicines use and the application of antiretroviral therapy in resource-constrained settings. He is a Senior Lecturer in the Division of Pharmacology, Discipline of Pharmaceutical Sciences, School of Health Sciences, University of KwaZulu-Natal, Durban, South Africa. He is also consultant pharmacist for the Centre for the AIDS Programme of Research in South Africa (CAPRISA) and non-executive Director of JEMBI Health Systems, a not-for-profit company focused on developing computer/IT-based healthcare solutions for the developing world. Mr Gray is a Visiting Fellow in the Faculty of Pharmacy, Rhodes University, Grahamstown. Mr Gray is a Fellow and Honorary Life Member of the Pharmaceutical Society of South Africa, a past President of the South African Association of Hospital and Institutional Pharmacists, a past President of the Hospital Pharmacy Section, past Chairman of the Board of Pharmaceutical Practice and currently a Vice-President and Fellow of the International Pharmaceutical Federation (FIP). He has been a member of the Scheduling and Naming Expert Committee of the South African Medicines Control Council since 2000 and was appointed to the National Essential Medicines List Committee in 2012. He is a Member of the World Health Organization’s Expert Panel on Drug Policies and Management and has served as a member, rapporteur and co-chairperson of the Expert Committee on the Selection and Use of Essential Medicines, as chairperson of the sub-committee on Essential Medicines for Children, and on the WHO Guidelines Review Committee. Widely published, he has served as a reviewer for a number of international and local journals, is associate editor of the South African Pharmaceutical Journal and serves on the international editorial advisory boards of International Journal of Clinical Pharmacy, the Journal of Pharmaceutical Policy and Practice and the GaBI Journal. He has also been a member of the editorial committee of the South African Health Review. Mr Gray has reviewed funding applications for several agencies, including the Health Systems Trust, National Research Foundation, Medical Research Council and UNITAID.He has been actively involved in the development and assessment of medicines and other health-related law in South Africa.

 Researchgate Profile

 

List of Publications 
(last 5 years only)

 Peer-reviewed journals

 

1.       Godman B, Malmström RE, Diogene E, Gray A, Jayathissa S, Timoney A, Acurcio FA, Alkan A, Brzezinska A, Bucsics A, Campbell S, Czeczot J, de Bruyn W, Eriksson I, Faridah Aryani MY, Finlayson AE, Fürst J, Garuoliene K, Guerra Júnior AA, Gulbinovic J, Jan S, Joppi R, Kalaba M, Magnusson E, McCullagh L, Miikkulainen K, Ofierska-Sujkowska G, Pedersen H, Selke G, Sermet C, Spillane S, Supian A, Truter I, Vlahovic-Palcevski V, Vien LE, Vural EH, Wale J, Wladysiuk M, Zeng W, Gustafsson LL. Are new models needed to optimise the utilisation of new medicines to sustain healthcare systems? Expert Review of Clinical Pharmacology 2015; 8(1): 77-94.

2.       Gray A, Vawda Y. Health policy and legislation. In Padarath A, English R (eds). South African Health Review 2013/2014. Health Systems Trust, Durban, 2014 (ISSN 1025-1715).

3.       Day C, Gray A. Health and related indicators. In Padarath A, English R (eds). South African Health Review 2013/2014. Health Systems Trust, Durban, 2014 (ISSN 1025-1715).

4.        Babar Z, Gray A, Kiani A, Vogler S, Ballantyne P, Scahill S. The future of medicines use and access research: using the Journal of Pharmaceutical Policy and Practice as a platform for change? (editorial) Journal of Pharmaceutical Policy and Practice 2014; 7: 8.

5.       Gray A. Medicines shortages – unpicking the evidence from a year in South Africa. Australasian Medical Journal 2014; 7(5): 208-212.

6.        Wiseman R, Cohen K, Gray A, Jamaloodien K, Kredo T, Miot J, Parrish A, Taylor B, Blockman M. AGREE to disagree – critical appraisal and the publication of practice guidelines. South African Medical Journal 2014; 104(5): 345-346.

7.       Naidoo A, Naidoo K, Yende-Zuma N, Gengiah TN, Padayatchi N, Gray AL, Bamber S, Nair G, Abdool Karim SS. Changes to antiretroviral drug regimens during integrated TB-HIV treatment: results of the SAPiT trial. Antiviral Therapy 2014; 19(2): 161-169.

8.       Ford N, Shubber Z, Hill A, Vitoria M, Doherty M, Mills EJ, Gray A. Comparative efficacy of lamivudine and emtricitabine: a systematic review and meta-analysis of randomized trials. PLoS ONE 2013; 8(11): e79981. doi:10.1371/journal.pone.0079981.

9.       Gray A, Collins J, Milani B. Persisting pain in children – ensuring implementation of new guidelines. European Journal of Hospital Pharmacy – Science and Practice 2013; 20(5): 293–296. DOI:10.1136/ejhpharm-2013-000367

10.    Lutge EE, Gray A, Siegfried N. The medical use of cannabis for reducing morbidity and mortality in patients with HIV/AIDS. Cochrane Database of Systematic Reviews 2013, Issue 4. Art. No.: CD005175. DOI: 10.1002/14651858.CD005175.pub3.

11.    Richter M, Venter WDF, Gray A. Enabling HIV self-testing in South Africa. Southern African Journal of HIV Medicine 2012; 13(4): 186-187.

12.    Gray A. Generic policies – a globally-relevant implementation challenge (editorial). Generics and Biosimilars Initiative (GaBI) Journal 2012; 1(3) DOI: 10.5639/gabij.2012.0103-4.027.

13.    Govender D, Gray A. Knowledge of primary school teachers about asthma: a cross-sectional survey in the Umdoni sub-district, KwaZulu-Natal. South African Family Practice 2012; 54(4): 347-351.

14.    Gray A, Manasse HR, Jr. Medicines shortages – a complex global challenge. Bulletin of the World Health Organization 2012; 90(3): 158-158A. (this was the most down-loaded article in the Bulletin of the WHO in March 2012 – see http://www.who.int/bulletin/downloads2012/en/index.html)

15.    Gengiah TN, Holford NHG, Botha JH, Gray AL, Naidoo K, Abdool Karim SS. The influence of tuberculosis treatment on efavirenz clearance in HIV-tuberculosis co-infected patients. European Journal of Clinical Pharmacology 2012; 68(5): 689–695.

16.    Abdool Karim SS, Naidoo K, Grobler A, Padayatchi N, Baxter C, Gray AL, Gengiah T, Gengiah S, Naidoo A, Jithoo N, Nair G, El-Sadr WM, Friedland G, Abdool Karim Q. Integration of antiretroviral therapy with tuberculosis treatment. New England Journal of Medicine 2011;365:1492-1501.

17.    Gray A. WHO Essential Medicines List for Children: impact on patient outcomes? Pediatric Drugs 2011; 13(4): 209-211.

18.    Milani B, Magrini N, Gray A, Wiffen P, Scholten W. WHO calls for targeted research on the pharmacological treatment of persisting pain in children with medical illnesses. Evidence-Based Child Health 2011; 6: 1017–1020.

19.    Holloway K, Mathai E, Gray A, on behalf of the Community-Based Surveillance of Antimicrobial Use and Resistance in Resource-Constrained Settings Project Group. Surveillance of antimicrobial resistance in resource-constrained settings – experience from five pilot projects. Tropical Medicine and International Health 2011; 16(3): 368-374.

20.    Holloway K, Mathai E, Gray A, on behalf of the Community-Based Surveillance of Antimicrobial Use and Resistance in Resource-Constrained Settings Project Group. Surveillance of community antimicrobial use in resource-constrained settings – experience from five pilot projects. Tropical Medicine and International Health 2011; 16(2): 152-161.

21.    Gengiah T, Gray A, Naidoo K, Abdool Karim Q. Initiating antiretrovirals during tuberculosis treatment: a drug safety review. Expert Opinion on Drug Safety 2011; 10(4): 559-574.

22.    Gray A, Tredree R. Implementing the Basel Statements on the Future of Hospital Pharmacy – a global challenge. International Pharmacy Journal 2010; 26(2): 32-34.

23.    Abdool Karim Q, Abdool Karim SS, Baxter C, Friedland G, Gengiah T, Gray A, Grobler A, Naidoo K, Padayatchi N, El-Sadr W.  The SAPIT trial provides essential evidence on risks and benefits of integrated and sequential treatment of HIV and tuberculosis. South African Medical Journal 2010; 100(12): 808-809.

24.    Richter M, Venter WDF, Gray A. Home self-testing for HIV: AIDS exceptionalism gone wrong. South African Medical Journal 2010; 100(1): 636-642.

25.    Karim QA, Karim SS, Frohlich JA, Grobler AC, Baxter C, Mansoor LE, Kharsany AB, Sibeko S, Mlisana KP, Omar Z, Gengiah TN, Maarschalk S, Arulappan N, Mlotshwa M, Morris L, Taylor D; on behalf of the CAPRISA 004 Trial Group. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010; 329(5996): 1168-1174.

26.    Gray A, Holloway K. Is WHO’s Essential Medicines List contributing to rational medicines use in developing countries? (Abstracts for the 16th World Congress of Basic and Clinical Pharmacology, 17-23 July 2010, Copenhagen, Denmark). Basic & Clinical Pharmacology & Toxicology 2010; 107(Suppl 1): 7-8.

27.    Abdool Karim SS, Naidoo K, Grobler A, Padayatchi N, Baxter C, Gray A, Gengiah T, Nair G, Bamber S, Singh A, Khan M, Pienaar J, El-Sadr W, Friedland G, Abdool Karim Q. Timing of initiation of  antiretroviral drugs during tuberculosis therapy. New England Journal of Medicine 2010; 362: 697-706.

 

Book chapters and monographs

 

1.       Gray A, Suleman F. Pharmaceutical pricing in South Africa. In Babar Z (ed). Pharmaceutical Prices in the 21st Century. Springer International Publishing, Cham, 2015 (ISBN 978-3-319-12168-0)

2.       Gray AL, Vawda YA. TRIPS, Access to Medicines and Local Production in South Africa. In Lofgren H, Williams O (eds). The New Political Economy of Pharmaceuticals. Production, Innovation and TRIPS in the Global South. Palgrave Macmillan, Basingstoke, 2013 (ISBN: 978-0-230-28463-0, ISBN10: 0-230-28463-9).

3.       Day C, Gray A. Health and related indicators. In Padarath A, English R (eds). South African Health Review 2012/2013. Health Systems Trust, Durban, 2013 (ISBN 978-1-919839-73-8).

4.       Gray A, Vawda Y, Jack C. Health policy and legislation. In Padarath A, English R (eds). South African Health Review 2012/2013. Health Systems Trust, Durban, 2013 (ISBN 978-1-919839-73-8).

5.       Gray AL, Vitoria A (2012). Technical update on treatment optimization: pharmacological equivalence and clinical interchangeability of lamivudine and emtricitabine: a review of current literature. World Health Organization, Geneva, 2012 (ISBN 978-924-150381-5).

6.       Gray A, Vawda Y, Jack C. Health policy and legislation. In Padarath A, English R (eds). South African Health Review 2011. Health Systems Trust, Durban, 2012 (ISBN: 978-1-919839-71-4).

7.       Day C, Gray A, Budgell E. Health and related indicators. In Padarath A, English R (eds). South African Health Review 2011. Health Systems Trust, Durban, 2012 (ISBN: 978-1-919839-71-4).

8.       Gray A, Suleman F. Medicines for chronic non-communicable diseases. In Phaswana-Mafuya N, Tassiopoulos D (eds). Non-communicable diseases in developing countries. Nova Science Publishers, Hauppauge NY, 2011 (ISBN: 978-1-61209-996-5).

9.       Day C, Gray A. Health and related indicators. In Fonn S, Padarath A (eds). South African Health Review 2010. Health Systems Trust, Durban, 2010 (ISBN: 978-1-919839-69-1).

10.    Gray A, Hoffman J, Mansfield PR. Pharmaceutical sales representatives. In Mintzes B, Mangin D, Hayes L (eds). Understanding and responding to pharmaceutical promotion: a practical guide. World Health Organization/Health Action International, Amsterdam, 2010. (also available in French, Spanish and Russian editions)

11.   Gray A, Goodman B, Terán Puente JM, Mintzes B. Using unbiased prescribing information. In Mintzes B, Mangin D, Hayes L (eds). Understanding and responding to pharmaceutical promotion: a practical guide. World Health Organization/Health Action International, Amsterdam, 2010. (also available in French, Spanish and Russian editions)

12.   Gray A. The challenges of implementing antiretroviral treatment in South Africa. In Abdool Karim SS and Abdool Karim Q (eds). HIV/AIDS in South Africa (2nd edition). Cambridge University Press, Cape Town, 2010 (ISBN: 978-0-521-14793-4).

Unrefereed journals

 

1.       Gray A, Pharasi B. Taking stock – looking back over 20 years in order to look forward. South African Pharmaceutical Journal 2014; 81(5): 37-39.

2.       Gray A. Biosimilars in rheumatology – has South Africa “jumped the gun”? South African Rheumatology Journal 2013; 5(2): 12-15.

3.       Gray AL. Lessons from the FIP Centennial Congress and the Ministers’ Summit. South African Pharmaceutical Journal 2013; 80(3): 34-36.

4.       Gray A, Suleman F. Training for clinical pharmacists – plat du jour or smörgåsbord? South African Pharmaceutical Journal 2012; 79(2): 38-40.

5.       Gray A. Prescribing and dispensing by nurses – neglected steps in the legislative process. HIV Nursing 2010; 1(2): 28-31.

6.        Gray A. Global standards, South African practice – report of a workshop. South African Pharmaceutical Journal 2010; 77(5): 45-48.

7.       Gray A. Looking through the mirror … seeing the envisioned future? South African Pharmaceutical Journal 2010; 77(3): 50-51.

8.       Gray A. Collaborative practice – more than just task shifting. South African Pharmaceutical Journal 2010; 77(1): 44-47.